Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
Doctors are doing a study to see if a combination of medicines can help people with a certain kind of cancer called multiple myeloma. They want to find out if these medicines are safe and if they work well. The study will take about 6-24 months, but it could be shorter or longer depending on how the person's body reacts to the treatment.
Doctors are doing a study to see if a combination of medicines can help people with a certain kind of cancer called multiple myeloma. They want to find out if these medicines are safe and if they work well. The study will take about 6-24 months, but it could be shorter or longer depending on how the person's body reacts to the treatment.
*Third Opinion AI Generated Synopsis
Trial Summary
Doctors leading this study hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to people who have multiple myeloma that has gotten worse and is not responding to standard drugs that are used for treating multiple myeloma, including chimeric antigen receptor T-cell therapy. Participation in this research will last about 6 -24 months, but it may be less or more depending on your response to treatment.
Doctors leading this study hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to people who have multiple myeloma that has gotten worse and is not responding to standard drugs that are used for treating multiple myeloma, including chimeric antigen receptor T-cell therapy. Participation in this research will last about 6 -24 months, but it may be less or more depending on your response to treatment.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: